Table 2.
Noggin treatment in animal models of spinal cord injury
| Animal model | Mode of spinal cord injury | Noggin treatment | Dose and route of administration | Duration | References |
|---|---|---|---|---|---|
| Sprague-Dawley rats (female) | Contusion injury at T7 | Recombinant human Noggin protein | 1.2–2.4 μg/d intrathecal injections | 3 d to 10 wk | Hart et al., 2020 |
| Mice (female) | Contusion injury at T8 and T9 | Recombinant mouse Noggin protein | 15 ng/kg/d intrathecal injection with osmotic minipump | 1 wk | Xiao et al., 2010 |
| Sprague-Dawley rats | Transection injury at T10 | Recombinant Noggin protein | 1 µg/kg noggin injection | 1 to 7 d | Cui et al., 2015 |
| Sprague-Dawley rats (female) | Contusion injury at T9–T10 | Recombinant mouse Noggin protein | 17.8 μg/kg/d intrathecal injection with osmotic minipump | 2 wk | Matsuura et al., 2008 |
| Adult Sprague-Dawley rats (male) | Ligation of spinal nerve ligation at L5 (an animal model of neuropathic pain) | Recombinant Noggin protein | 5 µg/mL intrathecal injection | 1 to 7 d | Yang et al., 2019 |